Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108,074,661
-
Total 13F shares
-
91,862,480
-
Share change
-
-816,696
-
Total reported value
-
$130,443,350
-
Price per share
-
$1.42
-
Number of holders
-
95
-
Value change
-
-$2,093,251
-
Number of buys
-
51
-
Number of sells
-
64
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q2 2025
As of 30 Jun 2025,
Aclaris Therapeutics, Inc. - Common Stock (ACRS) was held by
95 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
91,862,480 shares.
The largest 10 holders included
BML Capital Management, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Vivo Capital, LLC, VANGUARD GROUP INC, BlackRock, Inc., Rock Springs Capital Management LP, Decheng Capital LLC, MILLENNIUM MANAGEMENT LLC, MORGAN STANLEY, and D. E. Shaw & Co., Inc..
This page lists
95
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.